SAM Chun Dang Pharm삼천당제약
000250 · KOSDAQ · ₩000250 · 삼천당제약
₩182,700▼ ₩5,900 (3.13%)End-of-day · Oct 30, 2026 · End-of-day prices.
Margins
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Gross margin | 47.4% | 47.2% | 47.3% | 50.3% | 50.7% | 49.7% |
| Operating margin | 6.8% | 3.7% | 1.3% | 5.0% | 6.9% | −9.1% |
| Net margin | 6.8% | 2.3% | −5.2% | −5.4% | 3.3% | −9.9% |
Growth (year on year)
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue growth | +12.1% | +9.9% | +9.5% | +8.6% | +6.0% | — |
| Operating income growth | +109.6% | +220.5% | −72.4% | −21.8% | +179.9% | — |
| Net income growth | +237.9% | +148.2% | −5.1% | −277.9% | +135.3% | — |
Returns
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Return on equity | 6.1% | 1.9% | −4.5% | −5.3% | 3.4% | −9.5% |
| Return on assets | 3.5% | 2.2% | −1.1% | −1.1% | 2.5% | −3.0% |
Leverage and liquidity
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Liabilities to equity | 43.6% | 54.4% | 48.8% | 36.7% | 52.0% | 37.4% |
| Net debt to equity | −3.7% | −14.1% | −17.3% | 2.6% | 11.5% | −4.9% |
| Current ratio | 221.1% | 226.9% | 259.6% | 282.8% | 413.4% | 312.7% |
Calculated from filed financial statements. TTM = trailing 12 months.
Also known as: SAM Chun Dang Pharm / 삼천당제약 / 000250 / KRX:000250
Source: KRX statistical information